The efficacy and safety of local therapy of atopic dermatitis in infants and school-age children

Atopic dermatitis is a multifactorial genetic inflammatory skin disease associated with disturbances of skin barrier function affected by predisposition to IgE-mediated hypersensitivity, which is characterized by itching, chronic recurrent course of the disease, age-related features of localization and lesion morphology, and requires the long-term and permanent treatment.
Treatment is based on the continuous use of emollients, topical calcineurin inhibitors, topical glucocorticoids, and hygienic skin care.
The mechanisms of the atopic dermatitis development are primarily based on a genetic predisposition to allergies, failure of the normal development of congenital and acquired factors of the immune system, as well as the influence of environmental factors and various trigger factors, such as allergenic (food, indoor, epidermal, fungal allergens, etc.). and non-allergenic (tobacco smoke, pollutants, psycho-emotional stress, concomitant chronic and acute diseases, mainly ARVI, etc.).
It has been established that atopic dermatitis is characterized by the epidermal barrier dysfunction leading to excessive tran-sepidermal water loss, increased permeability of the epidermis, the penetration of allergens and microbial agents via the skin and eventually to sensitization to allergens and the development of specific allergic skin inflammation and atopic march with the sequential development of other atopic diseases.
Modern therapeutic strategies are actively aimed at repairing the epidermal barrier, preventing sensitization and atopic march development. This article describes the features of the epidermal barrier dysfunction in atopic dermatitis, lists the methods of its restoration and ways to prevent subsequent exacerbations using local therapy and emollients, and presents 3 clinical cases.

1. Chatenoud L., Bertuccio P., Turati F., Galeone C., Naldi L., Chatenoud L. et al. Markers of microbial exposure lower the incidence of atopic dermatitis. Allergy. 2020;75(1):104-115. doi: 10.1111/all.13990.

2. Vinding G.R., Esmann S., Jemec G.B. Quality of life in atopic dermatitis: changes over 6 years in patients who report persistent eczema. J Dermatol. 2012;39(8):721-722. doi: 10.1111/j.1346-8138.2012.01512.x.

3. Khaitov R.M., Ilina N.I. Allergology and clinical immunology: clinical guidelines. Moscow: GEOTAR-Media; 2019. 352 p. (In Russ.)

4. Draelos Z.D. Clinical situations conducive to proactive skin health and anti-aging improvement. J Investig Dermatol Symp Proc. 2008;13(1):25-27. doi: 10.1038/jidsymp.2008.9.

5. Brown S.J., McLean W.H. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3):751-762. doi: 10.1038/jid.2011.393.

6. Kobayashi T., Glatz M., Horiuchi K., Kawasaki H., Akiyama H., Kaplan D.H. et al. Dysbiosis and Staphylococcus aureus colonization drives inflammation in atopic dermatitis. Immunity. 2015;42(4):756-766. doi: 10.1016/j.immuni.2015.03.014.

7. Flores G.E., Seite S., Henley J.B., Martin R., Zelenkova H., Aguilar L., Fierer N. Microbiome of affected and unaffected skin of patients with atopic dermatitis before and after emollient treatment. J Drugs Dermatol. 2014;13(11):1365-1372. Available at: https://pubmed.ncbi.nlm.nih.gov/25607704/.

8. Williams M.R., Gallo R.L. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep. 2015;15(11):65. doi: 10.1007/s11882-015-0567-4.

9. Kennedy E.A., Connolly J., Hourihane J.O., Fallon P.G., McLean W.H.I., Murray D. et al. Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J Allergy ClinImmunol. 2017;139(1):166-172. doi: 10.1016/j.jaci.2016.07.029.

10. Kim J., Kim B.E., Ahn K., Leung D.Y.M. Interactions Between Atopic Dermatitis and Staphylococcus aureus Infection: Clinical Implications. Allergy Asthma Immunol Res. 2019;11(5):593-603. doi: 10.4168/aair.2019.11.5.593.